NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, DIRECTLY OR INDIRECTLY, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION

FOR IMMEDIATE RELEASE

4 December 2018

RECOMMENDED CASH OFFER
for
BTG plc
("BTG")
by
Bravo Bidco Limited
("Bravo Bidco")
a newly incorporated entity indirectly wholly-owned by Boston Scientific Corporation
("Boston Scientific")

Update on irrevocable undertaking given by Invesco Asset Management Limited
("Invesco")

On 20 November 2018 the boards of Boston Scientific, Bravo Bidco and BTG announced the terms of a recommended cash offer to be made by Bravo Bidco for the entire issued and to be issued share capital of BTG at a price of 840 pence in cash per BTG Share (the "Rule 2.7 Announcement"). Defined terms in this announcement shall, except where defined in this announcement or the context requires otherwise, have the meanings given to them in the Rule 2.7 Announcement.

Included in the Rule 2.7 Announcement were details of irrevocable undertakings to support the offer including that received from Invesco, which gave an irrevocable undertaking in respect of 61,635,838 BTG Shares (the "Committed Shares").

Since the publication of the 2.7 Announcement, Invesco has contacted Bravo Bidco to request an amendment to its irrevocable undertaking, namely the insertion of a clause specifying that the undertaking will expire on 20 August 2019, being the date first set as the Long Stop Date in the Rule 2.7 Announcement. Bravo Bidco has agreed to this and certain other non-substantive amendments to correct certain typographical and clerical errors. All other terms of the Invesco irrevocable undertaking remain the same, including the total number of Committed Shares.

The amended undertaking (as well as a copy of this announcement) will be uploaded to the Boston Scientific website (http://investors.bostonscientific.com/) shortly.
Enquiries:

Bravo Bidco / Boston Scientific
Susie Lisa (Investor Relations) +1 (508) 683-5565

Barclays Bank PLC, acting through its Investment Bank (financial adviser to Bravo Bidco and Boston Scientific)
Douglas Solomon +44 (0) 20 7623 2323
Jed Brody
Derek Shakespeare

Barclays Bank PLC, acting through its investment bank ("Barclays"), which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively for Boston Scientific and Bravo Bidco and no one else in connection with the matters referred to in this announcement and will not be responsible to anyone other than Boston Scientific and Bravo Bidco for providing the protections afforded to clients of Barclays nor for providing advice in relation to the Acquisition or any other matter referred to in this announcement.

This announcement is for information purposes only and is not intended to, and does not, constitute or form part of any offer, invitation, inducement or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of or exercise rights in respect of any securities, or the solicitation of any vote or approval of an offer to buy securities in any jurisdiction, pursuant to the Acquisition or otherwise nor shall there be any sale, issuance or transfer of any securities pursuant to the Acquisition in any jurisdiction in contravention of any applicable laws.

The Acquisition will be implemented solely pursuant to the terms of the Scheme Document (or in the event that the Acquisition is to be implemented by means of a Takeover Offer, the Offer Document), which will contain the full terms and conditions of the Acquisition, including details of how to vote in respect of the Scheme. Any decision, vote or other response in respect of the Acquisition should be made only on the basis of information contained in the Scheme Document. BTG Shareholders are advised to read the formal documentation in relation to the Acquisition carefully once it has been dispatched.

This announcement does not constitute a prospectus or prospectus-equivalent document.

In accordance with Rule 26.1 of the Code, a copy of this announcement will be available at http://investors.bostonscientific.com/, by no later than 12 noon (London time) on 5 December 2018. The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.
Update on Irrevocable Undertaking - RNS